Kyoichiro Tsuchiya

Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction

Chikara Komiya, Kyoichiro Tsuchiya, Kumiko Shiba et al. · PLoS ONE · 2016 · 227 citations · Full text

Sglt2 Inhibitor Ipragliflozin, Liver Dysfunction, Fatty Liver Disease +18

FoxOs Integrate Pleiotropic Actions of Insulin in Vascular Endothelium to Protect Mice from Atherosclerosis

Kyoichiro Tsuchiya, Jun Tanaka, Shuiqing Yu et al. · Cell Metabolism · 2012 · 173 citations · Full text

Inflammation, Metabolic Syndrome, Insulin Signaling +12

Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH

Kumiko Shiba, Kyoichiro Tsuchiya, Chikara Komiya et al. · Scientific Reports · 2018 · 172 citations · Full text

FOXO1 inhibition yields functional insulin-producing cells in human gut organoid cultures

Ryotaro Bouchi, Kylie S. Foo, Haiqing Hua et al. · Nature Communications · 2014 · 120 citations · Full text

Developmental Biology, Gut-organ Axis, Metabolic Regulation +6

Aldosterone Induces Angiotensin Converting Enzyme Gene Expression via a JAK2-Dependent Pathway in Rat Endothelial Cells

Toru Sugiyama, Takanobu Yoshimoto, Kyoichiro Tsuchiya et al. · Endocrinology · 2005 · 95 citations · Full text

Hypertension, Aldosterone-induced Endothelial Dysfunction, Cardiovascular Pharmacology +19